ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

15 July 2021, 07:30 CEST, Belgium: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir’s innovative therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.

 

Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital

Liege, Belgium, 02 July 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the issuance of a put option notice, according to the terms of the capital commitment agreement signed with LDA Capital Limited on April 24, 20201 . Under the terms of this agreement, LDA Capital commits an amount of up to EUR 50 million in cash within a maximum of three years in exchange for new ordinary shares in Mithra. This is the second put option notice related to this agreement, after the first issued on May 29, 2020.

Mithra successfully renegotiates the earnouts relating to its Complex Therapeutics and acquires full licensing and distribution rights for Zoreline®

Liege, Belgium, 24 June 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is pleased to announce today the successful renegotiation of the earnouts linked to two products of its Complex Therapeutic portfolio: the Zoreline® implant and the Myring® contraceptive hormonal ring

Estelle® Oral Contraceptive Now Available In The United States

21 June 2021, 07:30 CEST – Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the US commercial launch of Estelle® under the trademark Nextstellis® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action.

Mithra Completes Recruitment of Covid-19 Phase II Study

Liege, Belgium, 17 June 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has completed recruitment of the Coronesta Phase II, aiming to assess the protective role of Estetrol in Covid-19 infection. Estetrol is a naturally occurring estrogen produced by the human fetus during pregnancy.

Nextstellis® Receives FDA Marketing Exclusivity And Phase III Data Published

27 May 2021, 07:30 CEST – Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce that the novel oral contraceptive Estelle® – under the trademark Nextstellis® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) – has been granted marketing exclusivity as a new chemical entity (NCE) from the US Food and Drug Administration (FDA). The exclusivity runs for five years from FDA approval of the New Drug Application for Nextstellis.

Mithra Announces European Approval of Estelle®

Liege, Belgium, 20 May 2021 –18:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is very pleased to announce that the European Commission has accepted the registration application for the novel combined oral contraceptive Estelle®. This decision follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) on 26 March 2021 and is valid for all Member States of the European Union.

Mithra’s General Meeting of Shareholders Approves the Renewal of its Board of Directors

Liege, Belgium, 20 May 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today held its Annual General Meeting of securities holders. All agenda items put to vote were approved, including the appointment of Directors for a two-year-mandate.

 

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 6 May 2021 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 1,023,000 new shares on May 6, 2021 for a total amount of EUR 3,500,520 as the result of the exercise of 620 subscription rights (warrants) pursuant to the warrant plan initiated on March 2, 2015.

Mithra takes note of François Fornieri’s indictment

Liege, Belgium, 28 avril 2021 – 21:15 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces having been informed of François Fornieri’s indictment of alleged insider dealing charges following his audition held in Liège today by the federal judicial police.

Mithra reminds that since February 04, 2021, Mr. Fornieri no longer performs any management functions within the company and that the CEO function is now assumed by Mr Leon Van Rompay. Therefore, the indictment of Mr. Fornieri does not have any impact on the operational management of the company’s activities. Following the recent approvals obtained for its contraceptive product Estelle®, Mithra is more than ever focused on its ambitious objectives.